Parametric Portfolio Associates’s Harvard Bioscience HBIO Stock Holding History

Parametric Portfolio Associates’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$211K	Buy	3,392 +1,540	+83%	+$91.1K	﹤0.01%	3422
2021 Q4	$131K	Sell	1,852 -795	-30%	-$56.5K	﹤0.01%	3512
2021 Q3	$185K	Sell	2,647 -13,566	-84%	-$1.08M	﹤0.01%	3453
2021 Q2	$1.35M	Buy	16,213 +14,765	+1,020%	+$1.04M	﹤0.01%	2642
2021 Q1	$79K	Sell	1,448 -133	-8%	-$6.47K	﹤0.01%	3988
2020 Q4	$68K	Buy	+1,581	New	+$59K	﹤0.01%	3920
2019 Q2	–	Sell	-1,280	Closed	-$55K	–	3974
2019 Q1	$55K	Buy	+1,280	New	+$46.4K	﹤0.01%	3883
2015 Q4	–	Sell	-1,636	Closed	-$62K	–	3962
2015 Q3	$62K	Buy	+1,636	New	+$76.1K	﹤0.01%	3232
2014 Q4	–	Sell	-4,799	Closed	-$196K	–	3994
2014 Q3	$196K	Sell	4,799 -7	-0.1%	-$322	﹤0.01%	3616
2014 Q2	$219K	Sell	4,806 -49	-1%	-$2.06K	﹤0.01%	3686
2014 Q1	$230K	Sell	4,855 -177	-4%	-$8.06K	﹤0.01%	3571
2013 Q4	$236K	Buy	5,032 +2,152	+75%	+$94K	﹤0.01%	3540
2013 Q3	$115K	Buy	2,880 +946	+49%	+$37.2K	﹤0.01%	3712
2013 Q2	$69K	Buy	+1,934	New	+$74K	﹤0.01%	3632

Other funds holding HBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

PAIM

Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parametric Portfolio Associates's HBIO Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Harvard Bioscience (HBIO) stake by 83% in Q1 2022, buying an estimated $91.1K and bringing the position to 3,392 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #3422.

Parametric Portfolio Associates first reported a position in HBIO in Q2 2013 and has held it in 14 quarters since. The position peaked at $1.35M in Q2 2021. 98 funds tracked by Wall St. Rank hold HBIO as of Q1 2022.

Parametric Portfolio Associates held 3,392 shares of Harvard Bioscience worth $211K as of Q1 2022.
Parametric Portfolio Associates bought 1,540 Harvard Bioscience shares in Q1 2022, an estimated $91.1K.
Harvard Bioscience made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3422 holding.
Parametric Portfolio Associates first reported a position in Harvard Bioscience in Q2 2013 and has held it in 14 quarters since.
Parametric Portfolio Associates's Harvard Bioscience position peaked at $1.35M in Q2 2021.
98 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.